The @IMI_AMYPAD Prognostic and Natural History Study has had a successful year💥
Visit our website to get an overview of the data accessibility, a snapshot of 2024, and a glimpse into the future with the #EuroPAD community ⤵️
amypad.eu/news/recent-news/a…
📢New paper out❗️We present the context-of-use of the robust and generalizable Centiloid scale in the clinical routine 🏥 and in the context of DMTs💊. What a timing after the amazing news from last Thursday on Lecanemab!🤓
Academia-EFPIA collaborations were key!
@IMI_AMYPAD
Does amyloid-PET quantification really support visual assessment❓ Yes❗
In this latest @IMI_AMYPAD paper, we show how the value of quant in challenging clinical cases 🧐
Check out the paper below 👇
@VGaribotto@SilviaMorbelli@FBarkhof
Honored to have been awarded the @alzheimernl Research Talent Award! 🤓 Extremely proud for my work to be recognized to have scientific and societal impact 🏥
Thanks to everyone who made this work possible 🙏
@FBarkhof@IMI_AMYPAD@AlzheimerAms@RikOssenkoppele @OskarHansson9
Today I will be presenting "Use of plasma p-tau217 to identify Aβ-positive cognitively unimpaired participants for clinical trials: A multicohort stud" at @CTADconference (OC-29, 4:40pm CEST).
➡️Thanks to the data sharing on "Opportunities & Challenges", the landscape of new insights in #neuroimaging did not have any secrets for us! Thank you all for your so amazing talks!! 👏 A focus on #PETimaging will come this afternoon for the 4th symposium, be ready! #EUMIND 🧠
We had a fantastic day yesterday at the @eumind_congress! If you're attending #EUMind2024, don’t miss @LECollij's presentation today on 'From @IMI_AMYPAD to #EuroPAD – creating a multi-cohort preclinical database to model AD disease trajectories.' #EUMIND
🚨New publication led by @LECollij ‼️
Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease” shows the exacerbating effects of a-synuclein co-pathology in Alzheimer's disease. Now published in @NatureComms !
nature.com/articles/s41467-0…
The @IMI_AMYPAD study is advancing research, aiming to improve #Alzheimer’s modelling efforts. This dataset includes cognition data, disease biomarkers, genetic and environmental risk factors, and other relevant variables. bit.ly/ADWorkbench
#AAIC24 started this morning with an interactive educational session on Amyloid PET Quantification. Thanks to all speakers & delegates🤗
👉Today stop by Poster 88788 from @emmaluckettneu1 "Associations between AD polygenic risk scores & global amyloid deposition in @IMI_AMYPAD"
New preprint from @IMI_AMYPAD out📢 Using a prospective study design, we showed that quantification🔢 of amyloid-PET scans🧠improves the visual assessment agreement🧐and confidence 💪between 5 readers. The study was enriched for challenging cases🤔.
medrxiv.org/cgi/content/shor…
It's a wrap🤩! What a great two days again at the #EuroPAD meeting, a growing European 🇪🇺 collaboration of several cohorts including @IMI_EPAD@IMI_AMYPAD. This year, we kicked off with two workshops 🤓 on advances in PET and MR imaging 🩻 Thanks @LuigiLorenzini1 @DavidVallez!
Great first time presentation by @LPieperhoff at #ADPD2024 about the @IMI_AMYPAD longitudinal imaging data! 😎
Note, the data is openly available, check out our website to gain access! 👇
AMYPAD.eu
PhD vacancy alert! 📣
Do you have experience with neuroimaging, programming skills, a fascination for the brain🧠, and would like to work in a highly international group? This position is for you!
Check out the website👇
werkenbij.amsterdamumc.org/e…@FBarkhof@HMutsaerts